Abstract
Neuroendocrine differentiation has been described in rectal adenocarcinomas receiving neoadjuvant therapy prior to radical surgery, but its clinical relevance is controversial and no data are currently available in colorectal carcinoma metastases as compared to primary tumors. The presence of chromogranin A positive tumor cells was investigated by means of immunohistochemistry on surgical specimens from 54 primary colorectal carcinomas and their corresponding metastases, resected at diagnosis or during tumor progression. In 47 patients, tumor metastases were resected 1 month to 12 years after chemotherapy and/or radiotherapy, while in the remaining seven patients no additional therapy after primary surgery was performed. In primary tumors, neuroendocrine differentiation was found in 12/54 cases (22.2%) as compared to 25/54 metastatic lesions (46.3%; p = 0.01). The presence of neuroendocrine phenotype was not correlated with any clinical pathological parameter nor with a different proliferation index. However, patients having neuroendocrine cells in the primary tumor had a significantly shorter survival from the time of metastatic spread than those having not (33.3 vs. 55.5 months; p = 0.04). In summary, our data show that colorectal carcinoma metastases contain a higher percentage of neuroendocrine differentiated cells as compared to their corresponding primaries, a finding possibly related to the influence of chemotherapy in neuroendocrine differentiation during colorectal carcinoma progression.
Similar content being viewed by others
References
Pagani A, Papotti M, Abbona GC, Bussolati G (1995) Chromogranin gene expression in colorectal adenocarcinomas. Mod Pathol 8:626–632
Abbona G, Papotti M, Viberti L, Macrĭ L, Stella A, Bussolati G (1998) Chromogranin A gene epression in non-small cell lung carcinomas. J Pathol 186:151–156
Righi L, Sapino A, Marchiò C, Papotti M, Bussolati G (2010) Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Semin Diagn Pathol 27:69–76
López-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernadó L, Menendez JA (2008) Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and imunohistochemical profiling. Oncol Rep 20:1369–1374
Berruti A, Bollito E, Cracco CM, Volante M, Ciccone G, Porpiglia F, Papotti M, Scarpa RM, Dogliotti L (2010) The prognostic role of immunohistochemical chromogranin A expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. Prostate 70:718–726
Jiang SX, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I (2006) Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol 30:945–953
Howe MC, Chapman A, Kerr K, Dougal M, Anderson H, Hasleton PS (2005) Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 46:195–201
Segawa Y, Takata S, Fujii M, Oze I, Fujiwara Y, Kato Y, Ogino A, Komori E, Sawada S, Yamashita M, Nishimura R, Teramoto N, Takashima S (2009) Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. J Cancer Res Clin Oncol 135:1055–1059
van Krimpen C, Elferink A, Broodman CA, Hop WC, Pronk A, Menke M (2004) The prognostic influence of neuroendocrine differentiation in breast cancer: results of a long-term follow-up study. Breast 13:329–333
Pelosi G, Pasini F, Sonzogni A, Maffini F, Maisonneuve P, Iannucci A, Terzi A, De Manzoni G, Bresaola E, Viale G (2003) Prognostic implications of neuroendocrine differentiation and hormone production in patients with stage I nonsmall cell lung carcinoma. Cancer 97:2487–2497
Mori M, Mimori K, Kamakura T, Adachi Y, Ikeda Y, Sugimachi K (1995) Chromogranin positive cells in colorectal carcinoma and transitional mucosa. J Clin Pathol 48:754–758
Cho YB, Yang SS, Lee WY, Song SY, Kim SH, Shin HJ, Yun SH, Chun HK (2010) The clinical significance of neuroendocrine differentiation in T3–T4 node-negative colorectal cancer. Int J Surg Pathol 18:201–206
Grabowsky P, Schindler I, Anagnostopoulos I, Foss HD, RieckenEO MU, Stein H, Berger G, Buhr HJ, Scherubl H (2001) Neuroendocrine differentiation is a relevant prognostic factor in stage III–IV colorectal cancer. Eur J Gastroenterol Hepatol 13:405–411
Shia J, Tickoo SK, Guillem JG, Qin J, Nissan A, Hoos A, Stojadinovic A, Ruo L, Wong WD, Paty PB, Weiser MR, Minsky BD, Klimstra DS (2002) Increased endocrine cells in treated rectal adenocarcinomas. A possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapy. Am J Surg Pathol 26:863–872
Tampellini M, Brizzi MP, Bitossi R, Alabiso I, Sculli CM, Chiusa L, Papotti M, Dogliotti L (2007) Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy. J Cancer Res Clin Oncol 133:783–785
Borges M, Linnoila RI, van de Velde HJ, Chen H, Nelkin BD, Mabry M, Baylin SB, Ball DW (1997) An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 386:852–855
Rapa I, Ceppi P, Bollito E, Rosas R, Cappia S, Bacillo E, Porpiglia F, Berruti A, Papotti M, Volante M (2008) Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Mod Pathol 21:700–707
Ooi A, Hayashi H, Katsuda S, Nakanishi I (1992) Gastric carcinoma cells with endocrine differentiation show no evidence of proliferation. Hum Pathol 23:736–741
Hamada Y, Oishi A, Shoji T, Takada H, Yamamura M, Hioki K, Yamamoto M (1992) Endocrine cells and prognosis in patients with colorectal carcinoma. Cancer 69:2641–2646
De Bruine AP, Wiggers T, Beek C, Volovics A, von Meyenfeldt M, Arends JW, Bosman FT (1993) Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer 54:765–771
Ferrero S, Buffa R, Pruneri G, Siccardi AG, Pelagi M, Lee AK, Coggi G, Bosari S (1995) The prevalence and clinical significance of chromogranin A and secretogranin II immunoreactivity in colorectal adenocarcinomas. Virchows Arch 426:587–592
Acknowledgments
This work is partially supported by grants from the Italian Ministry of University (ex-60%, Rome) to MV, MT, and MP.
Conflict of interest statement
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Volante, M., Marci, V., Andrejevic-Blant, S. et al. Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas. Virchows Arch 457, 521–527 (2010). https://doi.org/10.1007/s00428-010-0967-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-010-0967-8